Curt Rohlfing1, Steven Hanson2, Cas Weykamp3, Carla Siebelder3, Trefor Higgins4, Ross Molinaro5, Paul M Yip6, Randie R Little2. 1. Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, United States. Electronic address: RohlfingC@health.missouri.edu. 2. Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, United States. 3. European Reference Laboratory, Location Queen Beatrix Hospital, Winterswijk, The Netherlands. 4. DynaLIFE(DX) Diagnostic Laboratory Services, Edmonton, AB, Canada. 5. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States. 6. University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND: Hemoglobin C, D Punjab, E or S trait can interfere with hemoglobin A1c (HbA1c) results. We assessed whether they affect results obtained with 12 current assay methods. METHODS: Hemoglobin AA (HbAA), HbAC, HbAD Punjab, HbAE and HbAS samples were analyzed on one enzymatic, nine ion-exchange HPLC and two Capillary Electrophoresis methods. Trinity ultra(2) boronate affinity HPLC was the comparative method. An overall test of coincidence of least-squared linear regression lines was performed to determine if HbA1c results were statistically significantly different from those of HbAA samples. Clinically significant interference was defined as >7% difference from HbAA at 6 or 9% HbA1c compared to ultra(2) using Deming regression. RESULTS: All methods showed statistically significant effects for one or more variants. Clinically significant effects were observed for the Tosoh G8 variant mode and GX (all variants), GX V1.22 (all but HbAE) and G11 variant mode (HbAC). All other methods (Abbott Architect c Enzymatic, Bio-Rad D-100, Variant II NU and Variant II Turbo 2.0, Menarini HA-8180T thalassemia mode and HA-8180V variant mode, Sebia Capillarys 2 and Capillarys 3) showed no clinically significant differences. CONCLUSIONS: Several methods showed clinically significant interference with HbA1c results from one or more variants which could adversely affect patient care.
BACKGROUND: Hemoglobin C, D Punjab, E or S trait can interfere with hemoglobin A1c (HbA1c) results. We assessed whether they affect results obtained with 12 current assay methods. METHODS: Hemoglobin AA (HbAA), HbAC, HbAD Punjab, HbAE and HbAS samples were analyzed on one enzymatic, nine ion-exchange HPLC and two Capillary Electrophoresis methods. Trinity ultra(2) boronate affinity HPLC was the comparative method. An overall test of coincidence of least-squared linear regression lines was performed to determine if HbA1c results were statistically significantly different from those of HbAA samples. Clinically significant interference was defined as >7% difference from HbAA at 6 or 9% HbA1c compared to ultra(2) using Deming regression. RESULTS: All methods showed statistically significant effects for one or more variants. Clinically significant effects were observed for the Tosoh G8 variant mode and GX (all variants), GX V1.22 (all but HbAE) and G11 variant mode (HbAC). All other methods (Abbott Architect c Enzymatic, Bio-Rad D-100, Variant II NU and Variant II Turbo 2.0, Menarini HA-8180T thalassemia mode and HA-8180V variant mode, Sebia Capillarys 2 and Capillarys 3) showed no clinically significant differences. CONCLUSIONS: Several methods showed clinically significant interference with HbA1c results from one or more variants which could adversely affect patient care.
Authors: Randie R Little; Hubert Vesper; Curt L Rohlfing; Maria Ospina; Sekineh Safar-Pour; William L Roberts Journal: Clin Chem Date: 2004-11-24 Impact factor: 8.327
Authors: Shella K Mongia; Randie R Little; Curt L Rohlfing; Steve Hanson; Richard F Roberts; William E Owen; Mario A D'Costa; Christine A Reyes; Veronica I Luzzi; William L Roberts Journal: Am J Clin Pathol Date: 2008-07 Impact factor: 2.493
Authors: Chia-Ni Lin; Todd J Emery; Randie R Little; Steve E Hanson; Curt L Rohlfing; Stéphane Jaisson; Philippe Gillery; William L Roberts Journal: Clin Chim Acta Date: 2012-01-08 Impact factor: 3.786
Authors: Kuanysh Kabytaev; Shawn Connolly; Curt L Rohlfing; David B Sacks; Alexander V Stoyanov; Randie R Little Journal: Clin Chim Acta Date: 2016-04-22 Impact factor: 3.786
Authors: Michael R Lewis; Patricia R Sheehan; Myrlene A Staten; Lawrence S Phillips; Anastassios G Pittas Journal: Diabetes Care Date: 2017-10 Impact factor: 19.112
Authors: Zoran Gluvic; Milan Obradovic; Milena Lackovic; Vladimir Samardzic; Jelena Tica Jevtic; Magbubah Essack; Vladimir B Bajic; Esma R Isenovic Journal: J Clin Pharm Ther Date: 2019-11-17 Impact factor: 2.512
Authors: Kirsten S Dorans; Lydia A Bazzano; Lu Qi; Hua He; Lawrence J Appel; Jonathan M Samet; Jing Chen; Katherine T Mills; Bernadette T Nguyen; Matthew J O'Brien; Gabriel I Uwaifo; Jiang He Journal: Trials Date: 2021-02-01 Impact factor: 2.279